Latest News
-
Stock Market Live Updates: Market Likely To Open Flat; Nifty To Hold 22,350; Earnings In Focus -
Bajaj Group Stock Declares Rs. 60/Share Dividend: Buy Ahead of Record Date On 28 June? -
Rs 45/Share Dividend: Record Date In Due Course; Buy The IT Stock For Dividend Eligiblity? -
175% Dividend: TATA Group Stock Declares Q4 Results; Buy The Rekha Jhunjhunwala Portfolio Stock? -
2:15 Bonus: Tata Group's Penny Stock Below Rs 90, Gives 2,821% Returns In 5 Years: Announces Q4 Report Card -
Rs. 240/Share Dividend: May 7 Fixed As Record Date; Buy The IT Stock To Be Eligible? -
1:5 & 1:2 Split, Rs 6/Sh Dividend: Fertilizer Stock Coming Up With 600% Payout; Record, Payment Dates Fixed -
Cube Highways Trust Set to Acquire Seven Highway Assets Worth Rs 5,172 Crore -
1:10 Split, Rs 51 Dividend: Accumulate Tata Stock, TP Rs 170; Big Update On £1.25 Bn Investment -
Tech Mahindra Sets Three-Year Plan for Robust Growth and Market Leadership by FY27
Nifty Pharma Climbs Over 3%; 5 Constituents Out Of 10 Scale 52-Week High
Amid strong global cues, Indian indices in line with their Asian peers opened higher in trade on May 10, 2021 and continue to trade firm in the afternoon session. At the time of writing this report, Nifty was up 123 points at 14945. Broader markets also performed in line with Nifty Midcap 100 up 0.85%.
Among Nifty sectoral indices, Pharma sector outran all other indices with gains over 3% at the time of writing this report. In fact the Nifty Pharma index hit a new 52-week high of 14213.9 today.
All of the 10 Nifty Pharma constituents were trading higher with contribution from Sun Pharma, Divis Labs, Dr. Reddys Labs, Torrent Pharma and Aurobindo Pharma. The gains in the stock price of pharma shares remained in the range of 2 to more than 5%.
Pharma stocks that hit fresh 52-week high on May 10, 2021
| Scrip | 52-week high price reached on May 10, 2021 |
|---|---|
| Sun Pharma | Rs. 703.5 |
| Divis Laboratories | Rs. 4199 |
| Aurobindo Pharma | Rs. 1061.75 4.8% |
| Lupin | Rs. 1241.55 |
| Cadila | Rs. 629 |
Talking specifically about the pharma sector, market experts suggest the pharma space to outperform in the medium term of say 3-5 years. Recent stimulus for pharma has been the RBI's liquidity shot to boost healthcare infrastructure amid raging coronavirus second wave in the country. In the short term FY22 is expected to be an excellent year pharma given the Covid-led demand.
GoodReturns.in
